Vor bio prices underwritten offering of common stock and concurrent private placement for aggregate proceeds of $115.8 million

Cambridge, mass., dec. 07, 2022 (globe newswire) -- vor bio (nasdaq: vor), a clinical-stage cell and genome engineering company, today announced the pricing of an underwritten offering and a private placement, with combined gross proceeds of approximately $115.8 million.
VOR Ratings Summary
VOR Quant Ranking